Project Grant R01NS138021
Award Date 8/1/25
Completion Date 7/31/30
Dollars Obligated $559K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Charleston, SC 29425, USA
Similar Awards
- This federal Project Grant award of $604,852.00 was provided by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program. The grant supports research to investigate the role of glial progenitor cells in the initiation and recurrence of medulloblastoma, the most common malignant childhood brain tumor. The research aims to advance the understanding of tumor heterogeneity,...
- This Project Grant award, valued at $611,591.00 and provided by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) federal grant program, aims to research new strategies to overcome therapy resistance in Hedgehog pathway-driven medulloblastoma, the most common malignant pediatric brain cancer. The key focus areas of this research project include: 1) investigating a new...
- This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, aims to develop novel small molecule inhibitors targeting the MBD2 protein for epigenetic therapy of medulloblastoma (MB), a common and aggressive pediatric brain cancer. The $564,045 award supports medicinal chemistry optimization of a lead compound, KCC07, which has shown promise in...
- The National Institute of Neurological Disorders and Stroke (NINDS) awarded a $773,607 Project Grant under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) to The Johns Hopkins University. The grant supports the development of brain-penetrant, histone evicting anthracycline drugs for the treatment of diffuse midline glioma (DMG), an aggressive and incurable form of pediatric brain cancer. The researchers are working to develop novel anthracycline...
- The National Institute of Neurological Disorders and Stroke (NINDS) awarded a $190,485 Project Grant under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) to Trustees of Indiana University (Indiana University Indianapolis) on February 4, 2025. The grant supports research to investigate the molecular mechanisms underlying differentiation failure in neuroepithelial stem cells with NF2 gene mutations, with the goal of identifying novel therapeutic...
- The National Institute of Neurological Disorders and Stroke (NINDS) awarded a 24-month, $430,375 Project Grant (CFDA 93.853) to Emory University to develop human organoid models for pediatric high-grade gliomas (PHGGs). The research aims to 1) create PHGG organoid models using human patient-derived cancer stem cells and 2) model how interactions between PHGG cells and the human neural microenvironment affect responses to tyrosine kinase inhibitors and other anti-tumor drugs. The goal is to...
- The National Institute of Neurological Disorders and Stroke (NINDS) awarded a $209,910 Project Grant under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) to The Regents of the University of California, San Francisco (UCSF) on August 1, 2025. The grant supports a 2-year research project to conduct mechanistic and functional genomic analysis of genes associated with meningioma radiotherapy response. The goal is to better understand the biology of...
- This $443,354 federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program supports research to investigate targeting the hexosamine biosynthetic pathway as a potential treatment for pediatric brain tumors. The research aims to understand how this metabolic pathway supports the growth and apoptosis resistance of diffuse midline gliomas with the...
- The National Institute of Neurological Disorders and Stroke (NINDS) awarded a $147,486 Project Grant under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) to the Baylor College of Medicine. The grant supports research to define the role of the germline DAAM2 variant R414W in familial glioma, the most common subtype of primary brain tumor in adults. The research aims to investigate how this newly discovered DAAM2 variant contributes to glioma...
- The National Institute of Neurological Disorders and Stroke (NINDS), through its Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853), awarded a $420,251 Project Grant to Brigham & Women's Hospital Inc. on May 6, 2025. The grant supports the development of an encapsulated cell-based oncolytic virus therapy for the treatment of glioblastoma (GBM), the most lethal primary brain tumor. The research aims to enhance the therapeutic efficacy of engineered...